礼来(LLY)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

LLY 礼来

盘后交易 12-11 16:45:31 EST

584.04

-14.01

-2.34%

盘后582.00

-2.04-0.35%

16:40 EST

最高601.19	最低567.41	成交量561.04万
今开598.66	昨收598.05	日振幅5.65%
总市值5,252亿	流通市值5,243亿	总股本8.99亿
成交额32.60亿	换手率0.62%	流通股本8.98亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"LLY","market":"US","secType":"STK","nameCN":"礼来","latestPrice":584.04,"timestamp":1702328400000,"preClose":598.05,"halted":0,"volume":5610370,"hourTrading":{"tag":"盘后","latestPrice":582,"preClose":584.04,"latestTime":"16:40 EST","volume":260933,"amount":152394093.37222,"timestamp":1702330808853},"delay":0,"floatShares":897742262,"shares":899307237,"eps":5.521359,"marketStatus":"盘后交易","marketStatusCode":4,"change":-14.01,"latestTime":"12-11 16:45:31 EST","open":598.66,"high":601.19,"low":567.41,"amount":3260099214.5761,"amplitude":0.056484,"askPrice":585,"askSize":300,"bidPrice":581.5,"bidSize":20,"shortable":3,"etf":0,"ttmEps":5.521359,"exchange":"NYSE","tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1702342800000},"adr":0,"listingDate":102488400000,"adjPreClose":598.05,"adrRate":0,"dividendRate":0.007482,"preHourTrading":{"tag":"盘前","latestPrice":598.72,"preClose":598.05,"latestTime":"09:29 EST","volume":22755,"amount":13617575.926199999,"timestamp":1702304997967},"postHourTrading":{"tag":"盘后","latestPrice":582,"preClose":584.04,"latestTime":"16:40 EST","volume":260933,"amount":152394093.37222,"timestamp":1702330808853},"volumeRatio":2.467299},"requestUrl":"/m/hq/s/LLY","defaultTab":"news","newsList":[{"id":"2390660243","title":"药不能停？礼来减肥药停止服用后，减掉的体重缓慢反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=2390660243","media":"新浪财经","top":-1,"share":"https://www.laohu8.com/m/news/2390660243?lang=zh_cn&edition=full","pubTime":"2023-12-12 01:13","pubTimestamp":1702314835,"startTime":"0","endTime":"0","summary":"一份研究显示，停止使用礼来减肥药Zepbound一年之后，此前服药八个月的受试病患体重缓慢地反弹，之前减少的体重重新增加了一半。在实验88周之后，用药八个月后暂停的实验组患者，体重仍比用药前要少9.9%，其他持续服药的患者，则平均减重23.5%。此前就有研究显示，如果停用礼来和诺和诺德使用的GLP-1减肥药，有体重反弹的风险。礼来美股周一盘中跌3.83%，报575.16美元；诺和诺德短暂上涨后下跌，盘中跌0.58%，报96.08美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20231212012033824bb1ab&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20231212012033824bb1ab&s=b","is_publish_highlight":false},{"id":"2390363178","title":"更新版 1-研究：服用礼来公司 Zepbound 药物的患者在停止治疗后体重又会增加","url":"https://stock-news.laohu8.com/highlight/detail?id=2390363178","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2390363178?lang=zh_cn&edition=full","pubTime":"2023-12-12 00:10","pubTimestamp":1702311005,"startTime":"0","endTime":"0","summary":"    路透12月11日 - 周一发表在《美国医学会杂志》上的一项研究显示，服用礼来  减肥药的患者在停止治疗后体重大幅反弹。研究显示，肥胖且无糖尿病的患者在从礼来的替哌肽转为安慰剂治疗52周后，体重反弹了14%。礼来公司的替西帕肽以 Zepbound 品牌销售，用于减肥，并已作为 Mounjaro 用于 2 型糖尿病治疗。研究数据显示，那些继续接受治疗的患者在 52 周内体重又减轻了 5.5%。礼来公司的股票在上午的交易中下跌了2%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false},{"id":"2390363049","title":"礼来下跌3.09%，报579.56美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2390363049","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2390363049?lang=zh_cn&edition=full","pubTime":"2023-12-12 00:04","pubTimestamp":1702310685,"startTime":"0","endTime":"0","summary":"12月12日，礼来(LLY)盘中下跌3.09%，截至00:04，报579.56美元/股，成交9.05亿美元。财务数据显示，截至2023年09月30日，礼来收入总额247.71亿美元，同比增长16.63%；归母净利润30.51亿美元，同比减少29.17%。大事提醒：2024年2月1日，礼来将披露2023财年年报。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2023/12/12000438732260.shtml","is_publish_highlight":false},{"id":"2390509283","title":"礼来减肥药停止给药后，减掉的体重缓慢地反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=2390509283","media":"新浪财经","top":-1,"share":"https://www.laohu8.com/m/news/2390509283?lang=zh_cn&edition=full","pubTime":"2023-12-11 23:11","pubTimestamp":1702307513,"startTime":"0","endTime":"0","summary":"　　一份研究结果显示，在该公司在试验12个月并停止给药Zepbound之后，受试病患的体重缓慢地反弹，丧．．．。礼来制药短线跳水，日内整体跌约2.4%，刷新日低至582.86美元。诺和诺德股价转涨。　　市场有风险，投资需谨慎。本文不构成个人投资建议，也未考虑到个别用户特殊的投资目标、财务状况或需要。用户应考虑本文中的任何意见、观点或结论是否符合其特定状况。据此投资，责任自负。股市回暖，抄底炒股先开户！智能定投、条件单、个股雷达……","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2023-12-11/doc-imzxsmap1581882.shtml","is_publish_highlight":false},{"id":"2390635795","title":"礼来涨0.37% 股价突破600美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2390635795","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2390635795?lang=zh_cn&edition=full","pubTime":"2023-12-11 22:30","pubTimestamp":1702305030,"startTime":"0","endTime":"0","summary":"北京时间2023年12月11日22时30分，礼来股票出现异动，股价快速拉升0.37%。截至发稿，该股报600.25美元/股，成交量3.1719万股，换手率0.00%，振幅0.01%。礼来股票所在的制药行业中，整体涨幅为0.96%。其相关个股中，Im Cannabis Corp、阿索尔达生物、Flora Growth Corp涨幅较大，Redhill Biopharma Ltd、惠普森医药、Sonoma Pharmaceuticals Inc较为活跃，换手率分别为8.30%、0.72%、0.37%，振幅较大的相关个股有Zomedica Corp、Amneal Pharmaceuticals Inc、Ani Pharmaceuticals Inc，振幅分别为2.94%、1.69%、1.33%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202312112230317900ea79&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202312112230317900ea79&s=b","is_publish_highlight":false},{"id":"2390334403","title":"减肥药大热之际，诺德诺德和礼来明年恐成“输家”？","url":"https://stock-news.laohu8.com/highlight/detail?id=2390334403","media":"金十数据","top":-1,"share":"https://www.laohu8.com/m/news/2390334403?lang=zh_cn&edition=full","pubTime":"2023-12-11 17:43","pubTimestamp":1702287827,"startTime":"0","endTime":"0","summary":"估值偏高、行业竞争加剧以及缺乏关键催化剂将使减肥药生产商明年股价承压。","market":"us","thumbnail":"https://cdn-news.jin10.com/77e486d0-06c9-4a5a-bbb2-0b712808cb77.png/lite","type":0,"news_type":0,"thumbnails":["https://cdn-news.jin10.com/77e486d0-06c9-4a5a-bbb2-0b712808cb77.png/lite"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://xnews.jin10.com/webapp/details.html?id=128429&type=news&data_type=0","is_publish_highlight":false},{"id":"2390319603","title":"上涨动力提前被透支？最新调查：“减肥药双雄”明年或成股市输家","url":"https://stock-news.laohu8.com/highlight/detail?id=2390319603","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2390319603?lang=zh_cn&edition=full","pubTime":"2023-12-11 17:36","pubTimestamp":1702287371,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，根据一项最新调查，受访者认为，与今年股票市场上的其他明星股相比，减肥药制造商诺和诺德和礼来更有可能在2024年成为“输家”。在这项针对518名受访者的调查中，约34%的受访者认为减肥药制造商作为今年股市上的赢家，在明年很可能会变成输家。今年，诺和诺德成为了欧洲市值最高的上市公司，并且，礼来的股价也飙升了约60%，这是因为这两家制药商的减肥药取得了成功，这引发了资本市场对制药企业的“淘金热”。","market":"us","thumbnail":"https://static.tigerbbs.com/dadce0ca7ebf72db095630eac92aca25","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/dadce0ca7ebf72db095630eac92aca25"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1036280.html","is_publish_highlight":true},{"id":"2390862831","title":"礼来上涨1.24%，报595.56美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2390862831","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2390862831?lang=zh_cn&edition=full","pubTime":"2023-12-09 02:26","pubTimestamp":1702059976,"startTime":"0","endTime":"0","summary":"12月9日，礼来(LLY)盘中上涨1.24%，截至02:26，报595.56美元/股，成交6.22亿美元。财务数据显示，截至2023年09月30日，礼来收入总额247.71亿美元，同比增长16.63%；归母净利润30.51亿美元，同比减少29.17%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2023/12/09022638716415.shtml","is_publish_highlight":false},{"id":"2389210070","title":"礼来下跌1.26%，报581.83美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2389210070","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2389210070?lang=zh_cn&edition=full","pubTime":"2023-12-07 22:37","pubTimestamp":1701959826,"startTime":"0","endTime":"0","summary":"12月7日，礼来(LLY)盘中下跌1.26%，截至22:37，报581.83美元/股，成交7159.41万美元。财务数据显示，截至2023年09月30日，礼来收入总额247.71亿美元，同比增长16.63%；归母净利润30.51亿美元，同比减少29.17%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2023/12/07223738703032.shtml","is_publish_highlight":false},{"id":"2389705832","title":"医线药事｜礼来可逆BTK抑制剂在华申报上市 O药新适应症申报上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2389705832","media":"每日经济新闻","top":-1,"share":"https://www.laohu8.com/m/news/2389705832?lang=zh_cn&edition=full","pubTime":"2023-12-06 09:53","pubTimestamp":1701827603,"startTime":"0","endTime":"0","summary":"每经记者：陈星每经编辑：魏官红1.礼来可逆BTK抑制剂在华申报上市12月5日，CDE网站显示，礼来可逆BTK抑制剂匹妥布替尼在华申报上市，适应症为既往接受过BTK抑制剂治疗的复发或难治性套细胞淋巴瘤成人患者。点评：BTK早已成为内卷赛道之一，全球已有6款BTK抑制剂获批上市，另有6款处于III期研究阶段。除Pirtobrutinib以外，已上市的BTK抑制剂均为一代BTK抑制剂，不可避免地存在C481S突变导致的获得性耐药问题，令其疗效大打折扣。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202312060953548233440b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202312060953548233440b&s=b","is_publish_highlight":false},{"id":"2389772319","title":"礼来可逆BTK抑制剂在华申报上市，搅局国内市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2389772319","media":"医药魔方","top":-1,"share":"https://www.laohu8.com/m/news/2389772319?lang=zh_cn&edition=full","pubTime":"2023-12-06 07:53","pubTimestamp":1701820410,"startTime":"0","endTime":"0","summary":"12月5日，CDE网站显示，礼来可逆BTK抑制剂匹妥布替尼在华申报上市，适应症为既往接受过BTK抑制剂治疗的复发或难治性套细胞淋巴瘤成人患者。该产品也成为了全球首款获FDA批准的可逆BTK抑制剂。BTK早已成为内卷赛道之一，全球已有6款BTK抑制剂获批上市，另有6款处于III期研究阶段。赛诺菲、诺华和罗氏3家的BTK抑制剂产品均是其中的代表。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202312060755398232e580&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202312060755398232e580&s=b","is_publish_highlight":false},{"id":"2389043771","title":"隔夜美股全复盘(12.6)| 三大股指小幅波动，涨跌不一，纳斯达克中国金龙指数收跌1.5%；苹果涨逾2%，总市值重返3万亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2389043771","media":"格隆汇","top":-1,"share":"https://www.laohu8.com/m/news/2389043771?lang=zh_cn&edition=full","pubTime":"2023-12-06 07:16","pubTimestamp":1701818167,"startTime":"0","endTime":"0","summary":"三大股指小幅波动，涨跌不一，纳斯达克中国金龙指数收跌1.5%；苹果涨逾2%，总市值重返3万亿美元","market":"us","thumbnail":"https://img7.gelonghui.com/column/2/140.png","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2/140.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/670877","is_publish_highlight":false},{"id":"2389425722","title":"Altimmune 首席执行官表示对与制药商合作和交易持开放态度","url":"https://stock-news.laohu8.com/highlight/detail?id=2389425722","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2389425722?lang=zh_cn&edition=full","pubTime":"2023-12-06 02:19","pubTimestamp":1701800360,"startTime":"0","endTime":"0","summary":"Pratik Jain/Khushi Mandowara    路透12月5日 - 减肥药开发商Altimmune  首席执行官Vipin Garg周二告诉路透，该公司对与大型制药商的交易和合作持开放态度，因为它正在积极寻找合作伙伴来推出和开发其试验性肥胖症药物。总部位于马里兰州盖瑟斯堡的Altimmune公司上周报告了培伐度肽的中期试验数据，数据显示该药有助于平均减轻15.6%的体重，并在治疗结束后继续减轻体重。Altimmune的股价在周二下跌了2.8%，报收于4.5美元，但自其肥胖症药物的中期数据公布以来，该公司的股价已上涨了42%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false},{"id":"2389721411","title":"更新版 1-更新 3-礼来肥胖症药物现已在美国药房上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2389721411","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2389721411?lang=zh_cn&edition=full","pubTime":"2023-12-06 01:10","pubTimestamp":1701796259,"startTime":"0","endTime":"0","summary":" Patrick  Wingrove/Manas Mishra    路透12月5日 - 礼来  周二表示，其最近获批的肥胖症治疗药物Zepbound现已在美国药房上市，医保不包括该药物的客户每月可支付550美元，即上市价格的一半。礼来公司表示，其商业储蓄卡计划现已在连锁药店推出。当美国食品和药物管理局于 11 月批准 Zepbound  时，礼来公司表示它将在美国感恩节假期后上市。礼来的肥胖症药物与之前获批的糖尿病药物 Mounjaro 的活性成分 tirzepatide 相同，后者自 2022 年上市以来一直被用于标签外减肥。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false},{"id":"2389725580","title":"更新 3-礼来公司的肥胖症药物现已在美国药房上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2389725580","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2389725580?lang=zh_cn&edition=full","pubTime":"2023-12-05 23:32","pubTimestamp":1701790349,"startTime":"0","endTime":"0","summary":" Manas Mishra/Patrick  Wingrove    路透12月5日 - 礼来  周二表示，其最近获批的肥胖症治疗药物Zepbound现已在美国药店上市，医保不包括该药物的客户每月可支付550美元，即上市价格的一半。礼来公司表示，其商业储蓄卡计划现已在连锁药店推出。美国食品和药物管理局于 11 月批准了 Zepbound，礼来公司当时表示将在感恩节后上市。礼来的肥胖症药物与之前获批的糖尿病药物 Mounjaro 的活性成分 tirzepatide 相同，Mounjaro 自 2022 年上市以来一直在标签外用于减肥。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false},{"id":"2389774164","title":"礼来宣布：减肥药Zepbound登陆美国药房","url":"https://stock-news.laohu8.com/highlight/detail?id=2389774164","media":"华尔街见闻","top":-1,"share":"https://www.laohu8.com/m/news/2389774164?lang=zh_cn&edition=full","pubTime":"2023-12-05 21:59","pubTimestamp":1701784798,"startTime":"0","endTime":"0","summary":"礼来制药（LLY）表示，新款减肥药Zepbound在美国药房上架，被纳入药品福利管理师（PBM）主要配方。并将于12月15日被添加到Cigna Healthcare的商业配方。美国药房现在提供礼来商用储蓄卡计划，以帮助病患获取Zepbound。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20231205215959806b1770&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20231205215959806b1770&s=b","is_publish_highlight":false},{"id":"1129768803","title":"礼来：新款减肥药Zepbound登陆美国药房","url":"https://stock-news.laohu8.com/highlight/detail?id=1129768803","media":"老虎资讯综合","top":-1,"share":"https://www.laohu8.com/m/news/1129768803?lang=zh_cn&edition=full","pubTime":"2023-12-05 21:55","pubTimestamp":1701784508,"startTime":"0","endTime":"0","summary":"美国药房现在提供礼来商用储蓄卡计划，以帮助病患获取Zepbound。","market":"us","thumbnail":"https://static.tigerbbs.com/3d0d553f648fada96687eff185a6a911","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/3d0d553f648fada96687eff185a6a911"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true},{"id":"2389742594","title":"礼来(LLY.US)旗下减肥药物Zepbound在美上市 售价较诺和诺德(NVO.US)Wegovy低20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2389742594","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2389742594?lang=zh_cn&edition=full","pubTime":"2023-12-05 21:24","pubTimestamp":1701782659,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，礼来周二宣布，其减肥药物Zepbound在美国上市。据悉，六剂Zepbound的标价为1059.87美元，相较诺和诺德旗下减肥药Wegovy的售价低了约20%。今年，该药物的减重适应症获批，这也意味着礼来将在减肥领域直接与诺和诺德竞争。数据分析公司GlobalData此前的一份报告显示，到2031年，礼来减肥药Zepbound在美国的销售额将达到41亿美元，这将大约是诺和诺德旗下Wegovy届时预计的销售额的一半。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1033871.html","is_publish_highlight":false},{"id":"2389744997","title":"更新版 1-礼来公司的肥胖症药物现已在美国药房上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2389744997","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2389744997?lang=zh_cn&edition=full","pubTime":"2023-12-05 21:06","pubTimestamp":1701781595,"startTime":"0","endTime":"0","summary":"    路透12月5日 - 礼来制药公司  最近批准的肥胖症药物Zepbound现已在美国药店上市，一些投保客户可以每月550美元或清单价格的一半购买这种药物。该公司正通过其商业储蓄卡计划向成年人提供这种减肥药，在该计划下，有商业保险的人可能有资格以低至25美元的价格购买1个月或3个月的处方药。而没有商业保险的成年人则可以低至 550 美元的价格购买 1 个月的处方药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false},{"id":"2389799879","title":"礼来再次延长Point Biopharma要约收购截止日期","url":"https://stock-news.laohu8.com/highlight/detail?id=2389799879","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2389799879?lang=zh_cn&edition=full","pubTime":"2023-12-05 11:36","pubTimestamp":1701747380,"startTime":"0","endTime":"0","summary":"礼来周一再次延长了生物制药公司Point Biopharma Global股东向其出售股份的最后期限，因为投资者担心要约收购价格过低，参与度不高。礼来在第三次延期中将最后期限定为12月15日，收购价维持在每股12.5美元。礼来已于10月达成了14亿美元收购Point的交易。从那时起到上周五收盘，Point的股价上涨了一倍多。 Point Biopharma是放射性配体疗法的开发商，这是一种癌症靶向治疗方法，它将附着在肿瘤上的分子与杀死特定细胞的放射性粒子相结合。该公司预计将于本月晚些时候公布实验疗法 PNT2002 的后期研究结果，该疗法用于治疗一种晚期前列腺癌。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023120511381483d1f804&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023120511381483d1f804&s=b","is_publish_highlight":false}],"profile":{"websiteUrl":"http://www.lilly.com","stockEarnings":[{"period":"1week","weight":0.024},{"period":"1month","weight":-0.034},{"period":"3month","weight":0.0198},{"period":"6month","weight":0.3408},{"period":"1year","weight":0.6086},{"period":"ytd","weight":0.6347}],"compareEarnings":[{"period":"1week","weight":0.0024},{"period":"1month","weight":0.0525},{"period":"3month","weight":0.033},{"period":"6month","weight":0.0705},{"period":"1year","weight":0.1614},{"period":"ytd","weight":0.2034}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"礼来公司于1901年在印第安纳州注册成立，其前身是1876年由伊利·礼来上校在印第安纳州印第安纳波利斯创立的药品生产企业。公司发现，开发，制造和销售重要医药产品。公司的宗旨是将“关爱”与“发现”结合起来，为世界各地的人们创造更美好的生活。","yearOnYearQuotes":[{"month":1,"riseRate":0.488372,"avgChangeRate":0.009264},{"month":2,"riseRate":0.488372,"avgChangeRate":-0.006869},{"month":3,"riseRate":0.604651,"avgChangeRate":0.014998},{"month":4,"riseRate":0.545455,"avgChangeRate":0.019052},{"month":5,"riseRate":0.409091,"avgChangeRate":0.014113},{"month":6,"riseRate":0.590909,"avgChangeRate":0.021126},{"month":7,"riseRate":0.568182,"avgChangeRate":0.002184},{"month":8,"riseRate":0.409091,"avgChangeRate":0.00001},{"month":9,"riseRate":0.454545,"avgChangeRate":0.003204},{"month":10,"riseRate":0.590909,"avgChangeRate":0.014439},{"month":11,"riseRate":0.75,"avgChangeRate":0.027866},{"month":12,"riseRate":0.613636,"avgChangeRate":0.032416}],"exchange":"NYSE","name":"礼来","nameEN":"Eli Lilly"},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.19.1","shortVersion":"4.19.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"礼来(LLY)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供礼来(LLY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"礼来,LLY,礼来股票,礼来股票老虎,礼来股票老虎国际,礼来行情,礼来股票行情,礼来股价,礼来股市,礼来股票价格,礼来股票交易,礼来股票购买,礼来股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"礼来(LLY)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供礼来(LLY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}